|Bid||25.08 x 1000|
|Ask||25.53 x 1000|
|Day's Range||25.00 - 26.83|
|52 Week Range||25.00 - 55.12|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.75|
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
If you want to know who really controls Adaptive Biotechnologies Corporation (NASDAQ:ADPT), then you'll have to look...
Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a partnership with Illumina, Inc. (ILMN) to develop in-vitro diagnostic (IVD) test kits for Adaptive’s current and future portfolio of next-generation sequencing (NGS)-based immunodiagnostics. The test kits under development would expand the availability of Adaptive’s clonoSEQ® Assay for assessing and monitoring minimal residual disease (MRD) for the management of patients with certain blood cancers and immunoSEQ Dx™ Assay for pipeline applications.
Adaptive Biotechnologies Corporation (ADPT) today announced it has entered into a global agreement with Amgen for the use of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) across multiple drug development programs within the Amgen hematology portfolio.
Shares of Adaptive Biotechnologies Corp. fell 8.5% in premarket trade Wednesday after the company reported earnings that fell short of analysts' expectations and predicted lower-than-expected full-year revenue. Adaptive, which went public in June, reported late Tuesday a second-quarter loss of $16.4 million, or $1.23 a share, after a loss of $12.5 million, or $1.01 a share, in the year-earlier quarter. FactSet analysts had expected a loss of 14 cents a share. Revenue grew to $22.1 million from $11.6 million in the year-ago quarter, topping the FactSet consensus of $19.4 million. Adaptive said it was expecting 2019 revenue of between $78 million and $81 million. That was below the $81.9 million that analysts polled by FactSet had predicted. Shares of Adaptive have gained 115% since the company priced its IPO in June at $20 a share.
Adaptive Biotechnologies Corp. shares were down fractionally in the extended session Tuesday after the biotech company reported a narrower-than-expected loss. Adaptive Biotech shares declined 0.1% after hours, following a 2.6% rise in the regular session to close at $43.08. The company reported second-quarter loss of $16.4 million, or $1.23 a share, compared with a loss of $12.5 million, or $1.01 a share, in the year-ago period. The adjusted loss was $10.9 million. Revenue rose to $22.1 million from $11.6 million in the year-ago quarter. Analysts surveyed by FactSet had forecast a loss of $17.7 million on revenue of $19.4 million. The report was the company's first since going public in July. Shares have gained 115% since the company priced its IPO at $20 a share.
SEATTLE, Aug. 13, 2019 -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today reported financial results for the quarter ended June 30, 2019..
(Bloomberg) -- Shares in three of the year’s hottest IPOs, Uber Technologies Inc., Revolve Group Inc. and Fastly Inc., plunged Friday as the latest batch of newly listed companies reported some of the most disappointing results this earnings season.Uber shares ended Friday 6.8% lower after the ride-hailing company missed sales estimates. Revolve fell 15.6% after the fashion e-tailer reported earnings below expectations. And Fastly, which saw its shares dip below its IPO price intraday, declined 18.1% after reporting lighter than expected margins.The disappointment spread to other IPOs that have not even reported yet, with RealReal Inc. shares tumbling 23% to below its IPO price of $20.Call it an upset, given the hype that tends to follow IPOs. Among the nearly 20 freshly listed companies that reported earnings this week, the majority fell in the next session. IPOs are rising 0.2% on average following reports, lagging behind S&P 500 stocks, which climbed 5.3% on average, according to data compiled by Bloomberg.Other newcomers on deck to report earnings include Adaptive Biotechnologies Corp., Greenlane Holdings Inc., RealReal Inc., and Grocery Outlet Holding Inc. They are among the more well-received IPOs of this year with stocks that opened at least 40% above their offer prices. All are first-time reporters.Cross-border IPOs will be tested as well when China’s big brands So-Young International Inc. and Luckin Coffee Inc. do their show-and-tell.(Updates shares in 1st and 2nd paragraphs, adds RealReal shares in 3rd.)\--With assistance from Drew Singer.To contact the reporter on this story: Crystal Kim in New York at email@example.comTo contact the editors responsible for this story: Brad Olesen at firstname.lastname@example.org, Jennifer Bissell-Linsk, Richard RichtmyerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
SEATTLE, Aug. 07, 2019 -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial-stage biotechnology company that reads and translates the genetic code of the.
Adaptive Biotechnologies (ADPT) today announced that it will report financial results for the second quarter of 2019 after market close on Tuesday, August 13, 2019. Investors interested in listening to the conference call may do so by dialing (800) 361-2311 for U.S. callers or (409) 937-8761 for international callers (Conference ID: 3095467). Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
Adaptive Biotechnologies Corporation (ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system with the goal of developing personalized diagnostics and therapeutics to improve patient lives, today announced that the State of New York Clinical Laboratory Evaluation Program (CLEP) has approved the clonoSEQ® Assay for the detection and monitoring of minimal residual disease (MRD) in patients with B-cell blood cancers.
Microsoft (MSFT) has unveiled its next-generation video game console in the midst of contemplating Xbox production cuts in China.
Adaptive Biotechnologies Corporation (ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve patient lives, today announced the closing of its initial public offering of 15,000,000 shares of common stock, and the exercise in full of the underwriters’ option to purchase 2,250,000 additional shares of its common stock, at a public offering price of $20.00 per share. Goldman Sachs & Co. LLC, J.P. Morgan and BofA Merrill Lynch acted as joint lead book-running managers for the offering.